Bayer

Missouri court grants preliminary approval of Roundup™ class settlement to resolve current and future claims

05 Mar 2026

Financial News Conference on the Full Year 2025 Results

04 Mar 2026

Bayer delivers upgraded 2025 ambition, projects solid 2026, focused on strategic priorities

04 Mar 2026

Bayer reports encouraging results for next generation investigational targeted radionuclide therapy 225Ac-PSMA-Trillium in advanced metastatic prostate cancer

27 Feb 2026

Bayer’s radium-223 dichloride plus enzalutamide demonstrates significant overall survival benefit in the PEACE-3 trial in patients with metastatic castration-resistant prostate cancer with bone metastases

27 Feb 2026

Monsanto announces Roundup™ class settlement agreement to resolve current and future claims

18 Feb 2026

Bayer’s asundexian demonstrated a substantial, 26 percent reduction in stroke after a non-cardioembolic ischemic stroke or high-risk transient ischemic attack with no increase in ISTH major bleeding versus placebo

06 Feb 2026

Nubeqa™ (darolutamide) receives third approval in China for men with advanced prostate cancer

03 Feb 2026

Finerenone recommended for the treatment of patients with heart failure with LVEF ≥40% in the EU

30 Jan 2026

Bayer to Present New Phase III Data and Advancements of Radiology Portfolio at ECR 2026

26 Jan 2026

View details about the software product Informachine News Trackers